Literature DB >> 8380611

Western blotting in the serodiagnosis of Lyme disease.

F Dressler1, J A Whalen, B N Reinhardt, A C Steere.   

Abstract

There are currently no accepted criteria for positive Western blots in Lyme disease. In a retrospective analysis of 225 case and control subjects, the best discriminatory ability of test criteria was obtained by requiring at least 2 of the 8 most common IgM bands in early disease (18, 21, 28, 37, 41, 45, 58, and 93 kDa) and by requiring at least 5 of the 10 most frequent IgG bands after the first weeks of infection (18, 21, 28, 30, 39, 41, 45, 58, 66, and 93 kDa). When these definitions were tested in a prospective study of all 237 patients seen in a diagnostic Lyme disease clinic during a 1-year period and in 74 patients with erythema migrans or summer flu-like illnesses, the IgM blot in early disease had a sensitivity of 32% and a specificity of 100%; the IgG blot after the first weeks of infection had a sensitivity of 83% and a specificity of 95%. Among patients with indeterminate IgG responses by ELISA, 6 of 9 patients with active Lyme disease had positive blots compared with 2 of 34 patients with other illnesses (P < .001). Thus, Western blotting can be used to increase the specificity of serologic testing in Lyme disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8380611     DOI: 10.1093/infdis/167.2.392

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  197 in total

1.  Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe.

Authors:  U Hauser; G Lehnert; B Wilske
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

2.  Identifying diagnostic peptides for lyme disease through epitope discovery.

Authors:  G A Kouzmitcheva; V A Petrenko; G P Smith
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

3.  Epstein-Barr virus and cytomegalovirus infections cause false-positive results in IgM two-test protocol for early Lyme borreliosis.

Authors:  H A Goossens; M K Nohlmans; A E van den Bogaard
Journal:  Infection       Date:  1999 May-Jun       Impact factor: 3.553

Review 4.  Overdiagnosis and overtreatment of Lyme neuroborreliosis are preventable.

Authors:  A Prasad; D Sankar
Journal:  Postgrad Med J       Date:  1999-11       Impact factor: 2.401

Review 5.  Laboratory testing for Lyme disease: possibilities and practicalities.

Authors:  Kurt D Reed
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

6.  A European multicenter study of immunoblotting in serodiagnosis of lyme borreliosis.

Authors:  J Robertson; E Guy; N Andrews; B Wilske; P Anda; M Granström; U Hauser; Y Moosmann; V Sambri; J Schellekens; G Stanek; J Gray
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

7.  Spirochetal uveitis: Spectrum of clinical manifestations, diagnostic and therapeutic approach, final outcome and epidemiological data.

Authors:  Dimitrios Kalogeropoulos; Ioannis Asproudis; Maria Stefaniotou; Marilita Moschos; Constantina Gartzonika; Ioannis Bassukas; Spiros Konitsiotis; Haralampos Milionis; Georgios Gaitanis; Konstantinos Malamos; Chris Kalogeropoulos
Journal:  Int Ophthalmol       Date:  2021-07-23       Impact factor: 2.031

8.  Plasmid location of Borrelia purine biosynthesis gene homologs.

Authors:  N Margolis; D Hogan; K Tilly; P A Rosa
Journal:  J Bacteriol       Date:  1994-11       Impact factor: 3.490

9.  Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi.

Authors:  R A Kalish; J M Leong; A C Steere
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

10.  Humoral immune response to outer surface protein C of Borrelia burgdorferi in Lyme disease: role of the immunoglobulin M response in the serodiagnosis of early infection.

Authors:  B P Fung; G L McHugh; J M Leong; A C Steere
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.